Vedanta Biosciences
Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection
$60MGrowth
Role not disclosedAA
AMR Action Fund
Activity from announced rounds
Activity in this selectionstan-boland-a8b1bac1
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $77.1M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionTrellis Bioscience
Developing native human monoclonal antibodies to treat intractable infectious diseases
$9MSeries C
Role not disclosedCentauri Therapeutics
Develops immunotherapeutic treatments for antimicrobial infections
£6MSeries A+
Role not disclosed